Finanzen von Immix Biopharma Inc (IMMX)IMMXImmix Biopharma Inc

Evaluating the bottom line, Immix Biopharma, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -34.18%, provide a clear picture of how effectively IMMX converts its operational activities into shareholder value.

In the context of the broader market, IMMX competes directly with industry leaders such as ABUS and OBX. With a market capitalization of $784.79M, it holds a significant position in the sector. When comparing efficiency, IMMX's gross margin of N/A stands against ABUS's 100.00% and OBX's N/A. Such benchmarking helps identify whether Immix Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown significant growth in stock performance, with a year-to-date change of +156.72% and a 1-year change of +511.40%. However, it has negative net income, with the latest reported loss of $11,557,002 for Q2 2026.